It’s getting harder to get a preferred brand name for a new drug or biologic through the Food & Drug Administration. About two in five proprietary names proposed by drug sponsors are now turned down by FDA prior to the approval of a new product.
That’s a jump from FDA’s historical rejection rates. At the beginning of the decade, the agency tossed out about 33%...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?